Here's Why You Should Retain Glaukos Stock in Your Portfolio

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 34.9% so far this year compared with the industry’s 7.5% decline. The S&P 500 Index has increased 0.7% in the same time frame.Glaukos, with a market capitalization of $5.48 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-q ...